• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Cytokine ELISPOT Assay Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cytokine ELISPOT assay, a powerful experimental technique, can be used to measure cytokine secreting cells and assess the effects of immune-modulating therapies in oncology and immunology fields. With unrivaled expertise and experience in various immunotherapy discoveries and development, Creative Biolabs is confident in providing optimized cytokine ELISPOT assay service to best suit your program requirements.

As a Highly Sensitive, Quantitative Assay to Measure Cytokine Secreting Cells

As a highly sensitive, quantitative Assay, ELISPOT assays are easier to detect a much smaller amount of cytokine and chemokine produced by individual immune cells. ELISPOT assays use high-affinity antibodies against different epitopes of a single cytokine/chemokine.

Compared with ELISA, the ELISPOT assay can not only detect cytokine response at the single-cell level but also measure specific cytokine-producing cells with high sensitivity, even if the cytokine secreted into the supernatant is lower than the level detected by ELISA.

The Foundation of Cytokine ELISPOT Assay

Cytokine ELISPOT is based on the following principle: cytokines secreted by immune cells are captured by antibodies on a matrix, and a secondary detection antibody combines with a substrate to precipitate at the location of the captured cytokines to form visible spots.

The basic ELISPOT protocol is designed to quantify the number of cells secreting specific cytokine/chemokine. The critical first step involves binding the high-affinity anti-cytokine Ab to a solid matrix. When the cells of interest are incubated in the plate, they secrete the cytokine/chemokine of interest. Then, the interest secreted protein binds to the pre-captured Abs immediately. This binding protein is recognized by a secondary enzyme-linked Ab. A colorimetric substrate is used to produce a dark precipitate or "spot" that marks the location of the protein-producing cell. The resultant spots are permanent and can be quantified visually, microscopically, or electronically.

Cytokine ELISPOT Applications

• Detecting cytokine secreted
• High throughput epitope mapping
• Measuring and assessing the immune response of immune cells
• Monitoring immunogenicity of vaccines, cell therapies, and immune-modulating therapies (CAR-T, checkpoint inhibitors, cytokines, agonists, and adjuvants)

Creative Biolabs will be with you at every step of your way. For more details of our Cytokine ELISPOT assay service, please reach out to our scientists to learn how we can be involved in your project.

References

1. Ji, Niannian, and Thomas G. Forsthuber. "ELISPOT techniques." Multiple Sclerosis. Humana Press, New York, NY, 2014. 63-71.
2. Klinman DM, Nutman TB. ELISPOT assay to detect cytokine‐secreting murine and human cells. Current Protocols in Immunology. 1994 Jun;10(1): 6-19.
3. Tang Y, et al. The co-stimulation of anti-CD28 and IL-2 enhances the sensitivity of ELISPOT assays for the detection of neoantigen-specific T cells in PBMC. Journal of Immunological Methods. 2020 Sep 1; 484: 112831.